Anesthetic management with remimazolam for a pediatric patient with Duchenne muscular dystrophy

Yuta Horikoshi, MD, Norifumi Kuratani, MD, PhD, MPH, Ken Tateno, DDS, PhD, Hiroshi Hoshijima, DDS, PhD, Tina Nakamura, MD, Tsutomu Mieda, MD, PhD, Katsushi Doi, MD, PhD, Hiroshi Nagasaka, MD, PhD,∗

Abstract

**Rationale:** Duchenne muscular dystrophy (DMD) is the most common and most severe type of muscular dystrophy, and DMD patients are at risk for complications from general anesthesia due to impaired cardiac and respiratory functions as the pathological condition progresses. In recent years, advances in multidisciplinary treatment have improved the prognosis of DMD patients, and the number of patients requiring surgery has increased. Remimazolam is a benzodiazepine derivative similar to midazolam. Its circulatory stability and the fact that it has an antagonist make it superior to propofol.

There are no reports of pediatric patients with DMD undergoing total intravenous anesthesia with remimazolam.

**Patient concerns:** A 4-year-old boy was scheduled for single-incision laparoscopic percutaneous extraperitoneal closure for inguinal hernia under general anesthesia, but the surgery was postponed because his serum creatine phosphokinase level was extremely high.

**Diagnosis:** He was diagnosed with DMD. According to the results of the genetic test, exon deletion of the DMD gene was detected using multiplex ligation-dependent probe amplification, although he had no symptoms of DMD except for elevated serum levels of creatine phosphokinase, etc.

**Intervention:** He was admitted for the same surgical purpose. Anesthesia was induced with 3 mg of intravenously administered remimazolam. He lost the ability to respond to verbal commands. After the intravenous administration of 100 μg of fentanyl, a continuous infusion of remifentanil (1.0 μg/kg/min) and remimazolam (15 mg/h) was started, and the endotracheal tube was inserted smoothly after the administration of 10 mg of rocuronium with which the muscle twitches disappeared in train-of-four monitoring. At the end of the surgery, 15 mg of flurbiprofen was administered intravenously. After surgery, we injected 40 mg of sugammadex to confirm a train-of-four count of 100%.

**Outcomes:** Although the dose of remimazolam was reduced to 5 mg/h 30 minutes before the end of the surgery, it took 20 minutes after the discontinuation of remimazolam for the patient to open his eyes upon verbal command. On postoperative Day 2, he was discharged from the hospital without any complications.

**Lessons:** Remimazolam was shown to be safe to use for general anesthesia in a pediatric patient with DMD.

**Abbreviations:** DMD = Duchenne muscular dystrophy, ECG = electrocardiogram, TIVA = total intravenous anesthesia, TOF = train-of-four.

**Keywords:** anesthesia, duchenne muscular dystrophy, remimazolam

1. Introduction

Duchenne muscular dystrophy (DMD) is characterized as a progressive multisystem neuromuscular disorder. With DMD being the most common and most severe type of muscular dystrophy,1 DMD patients are at risk for complications under general anesthesia due to impaired cardiac and respiratory functions as the pathological condition progresses.2 In recent years, advances in multidisciplinary treatment have improved the...
prognosis of DMD patients, and the number of patients requiring surgery has increased.

Remimazolam is a benzodiazepine derivative similar to midazolam and is an intravenous anesthetic with excellent adjustability due to ultrashort-acting pharmacological characteristics for intravenous use. Its circulatory stability and the fact that it has an antagonist (flumazenil) make it superior to propofol.

To our knowledge, there are no reports of pediatric patients with DMD undergoing total intravenous anesthesia (TIVA) with remimazolam.

2. Case report

Four months ago, a 4-year-old boy (16 kg, 96 cm) was scheduled for single-incision laparoscopic percutaneous extraperitoneal closure for inguinal hernia and umbilical plasty under general anesthesia, but the surgery was postponed because he had an elevated (creatine phosphokinase) level of 41018 U/L (normal range, 124–248). On detailed examination, he was diagnosed with DMD. According to the results of the genetic testing, the deletion of exons 45–52 as the dystrophin-encoding DMD gene deletions were detected using multiplex ligation-dependent probe amplification, although he had no symptoms of DMD except for an elevated creatine phosphokinase level of 53398 U/L (normal range, 59–248), aspartate aminotransferase level of 572 U/L (normal range, 13–30), alanine aminotransferase level of 547 U/L (normal range, 10–42), lactate dehydrogenase level of 2745 U/L (normal range, 124–222), and aldolase level of 224.3 U/L (normal range, 2.7–7.5).

Premedication was not used. After arriving at the operating room, oxyhemoglobin saturation measured by pulse oximetry monitoring readings were performed. His oxyhemoglobin saturation measured by pulse oximetry level was 99% under room air. After 3 mg of intravenously administered remimazolam, he lost the ability to respond to verbal commands.

Then, noninvasive blood pressure monitoring, electrocardiogram (ECG), and bispectral index monitoring were performed. After the intravenous administration of 100 μg of fentanyl, a continuous infusion of remifentanil (1.0 μg/kg/min) and remimazolam (15 mg/h) was started, and the endotracheal tube was inserted smoothly after the administration of 10 mg of rocuronium into which the surgery, the total use of rocuronium was 10 mg, without additional doses. After the induction of general anesthesia, we maintained the remimazolam dose at 15 mg/h and maintained the remifentanil dose at 1.0 μg/kg/min. Intraoperatively, we determined the doses of remifentanil (1.0 μg/kg/min) and remimazolam (15 mg/h) with reference to our extensive experience with remimazolam in pediatric patients, the signs of his clinical depth, and the relatively high amplitude slow waves in the electroencephalography. However, the bispectral index values showed 70–75. We maintained the core body temperature at 37.5°C by using a forced-air warming system and blankets. Twenty-five μg of fentanyl was administered intravenously 20 minutes before the end of the surgery. At the end of the surgery, 15 mg of flurbiprofen axetil was administered intravenously. After the surgery, we injected 40 mg of sugammadex to confirm a TOF count of 100%. Although the dose of remimazolam was reduced to 5 mg/h 30 minutes before the end of the surgery, it took 20 minutes after the discontinuation of remimazolam for the patient to open his eyes upon verbal command. No flumazenil was administered to boost his recovery. A urine myoglobin examination at 1 hour postoperatively showed negative results. On postoperative Day 2, he was discharged from the hospital without any complications.

3. Discussion

This case report is the first to present the use of remimazolam under general anesthesia for single-incision laparoscopic percutaneous extraperitoneal closure for inguinal hernia in a pediatric patient with DMD. TIVA is preferred over inhalational anesthetics for patients with DMD. The use of inhalational anesthetics should be avoided since it has been reported that inhalational anesthetics increase the risk of rhabdomyolysis, which can result in hyperkalemia and cardiac arrest. There are some reports that TIVA with remifentanil has been safely performed for DMD patients compared to inhalation anesthesia. However, even propofol has been reported to cause rhabdomyolysis.

Because remimazolam does not produce injection site pain, which is common in propofol use, and there are reports that general anesthesia with remimazolam has been safely performed in other high-risk patients, we chose to use remimazolam for pediatric anesthesia. Although there are reports of using midazolam, a benzodiazepine receptor agonist similar to remimazolam, as a premedication, there are still no reports of remimazolam use for general anesthesia in DMD patients. As a benzodiazepine receptor agonist, remimazolam is an ultrashort-acting sedative/anesthetic and shows high affinity for γ-aminobutyric acid receptors. The drug includes the safety profile of benzodiazepines regarding hemodynamic stability with fast onset and offset characteristics and improved controllability.

Because there are cases reported in which even apparently healthy children, similar to our present case, suffer from hyperkalemia, resulting in cardiac arrest, careful monitoring, such as ECG monitoring, was required perioperatively in the present case. It is important to recognize that ECG abnormalities are present in infants and young children, as well as in older boys, and precede the development of functional evidence of systolic dysfunction or left ventricular enlargement. Fortunately, in the present case, echocardiography and ECG results were within the normal range.

Although forced vital capacity, the pulmonary function parameter is most frequently reported to have predictive value in assessing the risk of respiratory complications for patients with DMD, we could not obtain pulmonary function test data for our patient, despite trying to test his pulmonary function.

While depolarizing muscle relaxants, such as succinylcholine, are widely recognized to be contraindicated in patients with DMD, little information is available on the unfavorable response to nondepolarizing muscle relaxants, but there have been reports of delayed recovery from muscle relaxants in the present case, we used rocuronium, a nondepolarizing muscle relaxant and monitored the patient with a muscle relaxation monitor, but it did not cause any clinical problems.

In this clinical case, stable anesthesia management in a pediatric patient was possible, and postoperative complications, such as impaired respiration and heart functions, were not encountered using remimazolam.

In conclusion, remimazolam was shown to be safe to use for general anesthesia in a pediatric patient with DMD.
Author contributions

All authors have read and approved the final manuscript.
YH: Writing – original draft and collected the data
NK: Anesthetized the patient and critically revised the article for important intellectual content.
TK: Collected the data and critically revised the article for important intellectual content.
HH: Critically revised the article for important intellectual content.
TN: Collected the data
TM: Anesthetized the patient.
KD: Critically revised the article for important intellectual content.
HN: Collected the data and critically revised the article for important intellectual content.

Data curation: Ken Tateno.
Investigation: Tina Nakamura.
Supervision: Katsushi Doi.
Writing – original draft: Yuta Horikoshi.
Writing – review & editing: Hiroshi Nagasaka, Norifumi Kuratani, Hiroshi Hoshijima, Tsutomu Mieda.

References

[1] Suh C, Shen L, Zhang Z, Xie X. Therapeutic strategies for Duchene muscular dystrophy. Genes (Basel) 2020;11:837.
[2] Birnkrant DJ, Panitch HB, O. Benditt JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest 2007;132:1977–86.
[3] Muenster T, Mueller C, Forst J, et al. Anaesthetic management in patients with Duchenne muscular dystrophy undergoing orthopaedic surgery: a review of 232 cases. Eur J Anaesthesiol 2012;29:489–94.
[4] Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase III/III trial. J Anesth 2020;34:543–53.
[5] Yemen TA, Mcclain CM. Muscular dystrophy, anesthesia and the safety of inhalational agents revisited; again. Pediatr Anesth 2006;16:105–8.
[6] Muenster T, Schmidt J, Wick S, et al. Rocuronium 0.3 mg x kg-1 (ED95) induces a normal peak effect but an altered time course of neuromuscular block in patients with Duchenne’s muscular dystrophy. Paediatr Anaesth 2006;16:840–5.
[7] Ihmsen H, Schmidt J, Schwilden HS, et al. Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy. Anesthesiology 2009;110:1016–9.
[8] Hemphill S, McNamara L, Bellamy MC, et al. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth 2019;122:448–59.
[9] Morimoto Y, Yoshimatsu A, Yoshimura M. Anesthetic management for a patient with myotonic dystrophy with remimazolam. JA Clin Rep 2021;7:10.
[10] Ririe DG, Shapiro F, Sethna NF. The response of patients with Duchenne’s muscular dystrophy to neuromuscular blockade with vecuronium. Anesthesiology 1998;88:351–4.
[11] Apilalogullari S, Oc B, Kara I, et al. Unilateral spinal anesthesia in a pediatric patient with Duchenne muscular dystrophy: a case report. Paediatr Anaesth 2013;23:1106–7.
[12] Rogers WK, McDowell TS. Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures. IDrugs 2010;13:929–37.
[13] Girshin M, Mukherjee J, Clowney R, et al. The postoperative cardiovascular arrest of a 5-year-old male: an initial presentation of Duchenne's muscular dystrophy. Pediatr Anesthes 2006;16:170–3.
[14] Cripe LH, Tobias JD. Cardiac considerations in the operative management of the patient with Duchenne or Becker muscular dystrophy. Paediatr Anaesth 2013;23:777–84.